Generated by AI
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases. Dyne Therapeutics advances a pipeline of investigational medicines designed to deliver treatment directly to muscle tissue and, in some programs, the central nervous system through its proprietary FORCE platform. Its current programs address conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease, along with other rare skeletal, cardiac, and metabolic muscle disorders. The company’s work centers on disease-modifying approaches aimed at the underlying genetic causes of these conditions, positioning it as a specialized player in rare disease drug development. Dyne Therapeutics is headquartered in Waltham, Massachusetts.
Website1560 Trapelo Road
Waltham, MA, 02451
United States
The latest articles about DYN.
Summary of Sep 9's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
Summary of Sep 8's posts. Generated by AI.
Investors talking about DYN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.